Роль трансплантации гемопоэтических стволовых клеток в терапии взрослых больных острыми лейкозами

acute leukemias, transplantation, related and unrelated donors

1. Copelan E.A. Hematopoietic stem-cell transplantation. New Engl J Med 2006;354(17):1813–26.

2. Gluckman E., Rocha V., Chastang C.L. Blood hematopoietic stem cells biology and transplantation. Hematology Am Soc Hematol Educ Program 1999; 1–14.

3. Gratwohl A., Baldomero H., Schmid O. et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Tranplant 2005;36(7):575–90.

4. Anasetti C. Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells. Haematologica 2002;87(8) (Suppl):1–3.

5. Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M. et al. Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37(5):439–49.

6. Carreras E., Jimenez M., GomezGarcia V. et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006;37(1):33–40.

7. Fagioli F., Ricchiardi A., CarnevaleSchianca F. Non-myeloablative allogeneic hematopoietic stem cell transplantation. Haematologica 2002;87(8 Suppl):13–9.

8. Locatelli F., Zecca M., Rondelli R. et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000;95(5):1572–9.

9. Munker R., Gunther W., Kolb H.J. New concepts about graft-versus host and graft-versus-leukemia-reactions. A summary of the 5th International Symposium held in Munich, 21 and 22 March 2002. Bone Marrow Transplant 2002;30(9):549–56.

10. Slavin S., Nagler A., Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood 1998;91(3):756–63.

11. Urbano-Ispizua A., Rozman C., Pimentel P. et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002;100(2):724–7.

12. Афанасьев Б.В., Алмазов В.А. Родоначальные стволовые клетки человека. Л., Наука; 1985. с. 202.

13. Appelbaum F.R., Gilliland D.G., Tallman M.S. The biology and treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 1999;15–43.

14. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RIHSCT). Bone Marrow Transplant 2002;29(3):191–5.

15. Bacigalupo A., Oneto R., Lamparelli T. et al. Pre-emptive therapy of acute graftversus –host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001;28(12):1093–6.

16. Corradini P., Tarella C., Olivieri A. et al. Reduced-intensity conditioning followed by allografting of hematopoetic cells can produce clinical molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002;99(1):75–82.

17. Djulbegovic B., Seidenfeld J., Bonnell C., Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies. Cancer Control 2003;10(1):17–41.

18. Kassim A.A., Chinratanalab W., Ferrara J.L., Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: what is the best recipe? Bone Marrow Transplant 2005;36(7):565–74.

19. Maris M.B., Niederwieser D., Sandmaier B.M. et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102(6):2021–30.

20. Or R., Shapira M.Y., Resnick I. et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101(2):441–5.

21. Popplewell L.L., Forman S.J. Is there an upper age limit for bone marrow transplantation? Bone Marrow Transplant 2002;29(4):277–84.

22. Zander A.R., Kroger N., Schleuning M. et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003;32(4):355–61.

23. Antin J.H.,Childs R., Filipovich A.H. et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant 2001;7:473–85.

24. Novitzky N., Davison G.M. Immune reconstitution following hematopoietic stem-cell transplantation. Cytotherapy 2001;3(3):211–20.

25. Dasgupta R.K., Rule S., Johnson P. et al. Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant 2006;37(5):455–61.

26. McSweeney P.A., Niederwieser D., Shizuru J.A. et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing highdose cytotoxic therapy with graft-versustumor effects. Blood 2001;97(11):3390–400.

27. Niederwieser D., Maris M.,Shizuru J.A. et al. Low-dose total body irradiation (TBI) and fludarabin followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppresuin with cyclosporin and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101(4):1620–9.

28. Marks D.I., Lush R., Cavenagh J. et al. The toxicity and efficacy of donor lymphocyte infusions given after reducedintensity conditioning allogeneic stem cell transplantation. Blood 2002;100(9):3108–14.

29. Bethge W.A., Hegenbart U., Stuart M.J. et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103(3):790–5.

30. Виноградова О.А., Савченко В.Г., Домрачева Е.В. и др. Молекулярный цитогенетический мониторинг химеризма и минимальной остаточной болезни у пациентов с хроническим миелолейкозом после аллогенной и сингенной трансплантации костного мозга. Тер арх 2002;(7);38–44.

31. Billiau A.D., Fevery S., Rutgeerts O. et al. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versusleukemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002;100(5):1894–902.

32. Cornelissen J.J., Carston M., Kollman C. et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97(6):1572–7.

33. Kallianpur A. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? Bone Marrow Transplant 2005;35(1):1–16.

34. Gratwohl A., Baldomero H., Frauendorfer K. et al. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Tranplant 2006;37(12):1069–85.

35. Bolwell B. Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Tranplant 2003;32(9):853–61.

36. Leiper A.D. Non-endocrine late complications of bone marrow transplantation in childhood: part I. Br J Haematol 2002;118(1):3–22.

37. Sorror M., Maris M., Storb R. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912–9.

38. Vogelsang G.B. How I treat chronic graft-versus-host disease. Blood 2001;97(5):1196–201.

39. Баранова О.Ю., Волкова М.А., Френкель М.А. и др. Анализ результатов различных программ терапии острых миелоабластных лейкозов МО–М2, М4–М7 ФАБ-вариантами (по данным РОНЦ РАМН им. Н.Н. Блохина). Гематол трансфузиол 2003;(3):10–3.

40. Савченко В.Г., Паровичникова Е.Н., Глясова Г.А. и др. Результаты 2,5-летней работы Российского мультицентрового исследования по лечению острого миелоидного лейкоза у взрослых. Тер арх 1995;(7):8–12.

41. Савченко В.Г., Паровичникова Е.Н. Лечение острых лейкозов (Клинические иследования). М., МЕДпресс-информ; 2004. с. 223.

42. Buchner T., Hiddemann W., Wormann B. et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93(12):4116–24.

43. Giles F.J., Keating A., Goldstone A.H. et al. Acute myelod leukemia. Hematology Am Soc Hematol Educ Program 2002;:73–110.

44. Hoelzer D., Gokbuget N., Ottmann O. et al. Acute lymphoblastic leukemia. Hematology Am Soc Hametokl Educ Program 1999;:162–92.

45. Hoelzer D., Gokbuget N., Digel W. et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002;99(12):4379–85.

46. Annual meeting of the European Group for Blood and Marrow Transplantation. EBMT News 2003;13:3.

47. Bacigalupo A. Bone marrow or peripheral blood as a sourse of stem cells for allogeneic transplantation. Haematologica 2002;87(8 Suppl):4–8.

48. Davies S.M., Kollman C., Anasetti C. et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000;96(13):4096–102.

49. Deeg H.J., Storer B., Slattery J.T. et al. Conditioning with targeted busulfan and cyclophosphamide for hematopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100(4):1201–7.

50. Kern W., Haferlach T., Schoch C. et al. Early blast clearence by remission induction therapy is a majour independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1991 Trial. Blood 2003;101(1):64–70.

51. Appelbaum F. Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation. Leukemia 2005;19:171–5.

52. Glucksberg H., Storb R., Fefer A. et al. Clinical manifestations of graft-versushost disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18(4):295–304.

53. Handgretinger R., Lang P., Klingebiel T., Niethammer D. CD34 stem cell dose and development of extensive chronic graftversushost disease. Blood 2002;99(10):3875–7.

54. LeMaistre C.F., Loberiza F.R. Jr. What is quality in a transplant program? Biol Blood Marrow Transplant 2005;11(4):241–6.

55. Morton J., Hutchins C., Durrant S. Granulocyte-colony-stimulating factor (G-CSF) primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSFmobilized peripheral blood stem cells. Blood 2001;98(12):3186–91.

56. Ringden O., Labopin M., Bacigalupo A. et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002;20(24):4655–64.

57. Ringden O., Labopin M., Gorin N.C. et al. The dismal outcome in patients with acute leukemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Bone Marrow Transplant 2000;25(10):1053–8.

58. Ringden O., Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 2005;113(11–12):813–30.

59. Knechtli C.J., Goulden N.J., Hancock J.P. et al. Minimal residual disease status before allogeneic bone marroe transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92(11):4072–9.

60. Любимова Л.С., Савченко В.Г. , Менделеева Л.П. и др. Эффективность трансплантации аллогенного костного мозга у больных острыми лейкозами в фазе полной ремиссии и у больных хроническим миелолейком в хронической фазе. Тер арх 1999;(7):27–32.

61. Cornelissen J., Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005;:151–5.

62. Gupta V., Lazarus H.M., Keating A. Myeloablative conditioning regimen for AML allografts: 30 years later. Bone Marrow Transplant 2003;32(10):969–78.

63. Luger S., Sacks N. Bone marrow transplantation for myelodysplastic syndrome – who? when? and which? Bone Marrow Transplant 2002;30(4):199–206.

64. Song K.W., Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 2005;36(3):183–91.

65. Cassileth P.A., Harrington D.P., Appelbaum F.R. et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in the first remission. N Engl J Med 1998;339(23):1649–56.

66. Tallman M.S., Rowlings P.A., Milone G. et al. Effect of posremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000;96(4):1254–8.

67. Van der Straaten H.M., van Biezen A., Brand R. et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Hematologica 2005;90(10):1339–45.

68. Zittoun R.A., Mandelli F., Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myeloid leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332(4): 217–23.

69. Grimwade D., Walker H., Harrison G. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98(5):1312–20.

70. Licht J., Sternberg D. The molecular pathology of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005;:137–42.

71. Масчан А.А., Румянцев А.Г. Трансплантация гемопоэтических стволовых клеток у детей. М., Медицинское информационное агентство; 2003. с. 909.

72. Птушкин В.В., Селидовкин Г.Д., Чемишкян К.Л. и др. Применение аутологичных клеток предшественников гемопоэза из периферической крови для трансплантации у больных с гематопоэтическими и солидными новообразованиями после высокодозной химиотерапии. Гематол трансфузиол 1996;(1):9–13.

73. Птушкин В.В. Методы получения клеток-предшественников гемопоэза из периферической крови. Гематол трансфузиол 2000;(6):43–5.

74. Alamo J., Shahjahan M., Lazarus H. et al. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant 2005;36(6):517–23.

75. Kumar S., Chen M.G., Gastineau D. et al. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graftversus-host disease. Bone Marrow Transplant 2001;27(11):1133–40.

76. Ruutu T., Volin L., Parkkali T. et al. Cyclosporine, methotraxate, and methylprednisone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000;96(7):2391–8.

77. IBMTR/ABMTR 2002;9(1).

78. Papadopoulos E.B., Carabasi M.H, Castro-Malaspina H. et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998;91(3):1083–90.

79. Sucui S., Mandelli F., de Witte T. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR 1): an intention to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102(4):1232–40.

80. Lazarus H., Perez W., Klein J. et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukemia: a retrospective analysis from the center for International Blood and Marrow transplant research. Br J Hematol 2005;132:755–69.

81. Kanda Y., Сhiba S., Hirai H. et al. Allogeneic hemetopoietic stem cell transplantation from family members other than HLA-identical sibling over the last decade (1991–2000). Blood 2003;102(4):1541–7.

82. Blaise D., Maraninchi D., Michallet M. et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001;97(11):3669–71.

83. Przepiorka D., Smith T.L., Folloder J. et al. Risk factors for acute graft-versushost disease after allogeneic blood stem cell transplantation. Blood 1999;94(4):1465–70.

84. Neudorf S., Sanders J., Kobrinsky N. et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004;103(10):3655–61.

85. Remberger M., Kumlien G., Aschan J. et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8(12):674–82.

86. Bunjes D. The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. Cytotherapy 2001;3(3):175–88.

87. Flowers M.E., Parker P.M., Johnston L.J. et al. Comparison of chronic graft-versushost disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: longterm follow-up of a randomized trial. Blood 2002;100(2):415–9.

88. Koc S., Leisenring W., Flowers M.E.D. et al. Therapy of chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100(1):48–51.

89. Kroger N., Zabelina T., Kruger W. et al. In vivo T cell depletion with pretreatment anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002;29(8):683–9.

90. Lee S.J., Zahrieh D., Alyea E.P. et al. Comparison of T-cell depleted and nonT-cell-depleted unrelated donor transplantation for hematologic disease: clinical outcomes, quality of life, and costs. Blood 2002;100(8):2697–702.

91. Martino R., Caballero M.D., Simon J.A. et al. Evidence for graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenus leukemia and myelodysplastic syndromes. Blood 2002;100(6):2243–5.

92. Mohty M., Kuentz M., Michallet M. et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002;100(9):3128–34.

93. Mohty M., de Lavallade H., Ladaique P. et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005;19(6):916–20.

94. Hegenbart U., Niederwieser D., Sandmaier B.M. et al. Treatment for acute myelogenous leukemia by low-dose, totalbody, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;24(3):444–53.

95. Sayer H., Kroger M., Beyer J. et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003;31(12):1089–95.

96. De Lima M., Anagnostopoulos A., Munsell M. et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104(3):865–72.

97. Aversa F. Full haplotype mismatched hematopoietic stem cell transplants. Haematologica 2002;87(8 Suppl):9–12.

98. Ruggeri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097–100.

99. Martelli M.F., Aversa F., BacharLustig E. et al. Transplants across human leukocyte antigen barriers. Semin Hematol 2002;39(1):48–59.

100. Reisner Y., Martelli M.F. Transplantation tolerance induced by ‘mega dose’ CD34+ cell transplants. Exp Hematol 2000;28(2):119–27.

101. Ji S.-Q., Chen H.-R., Wang H.-X. et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant. 2002;30(12):861–6.

102. Lowenberg B., Griffin J., Tallman M. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003;:82–101.

103. Hessling J., Kroger N., Werner M. et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;119(3):769–72.

104. Gorin N. Autologous stem cell transplantation in acute myelocytic leukemia. Hematology Am Soc Hematol Educ Program 1999;:119–37.

105. Strodtbeck D., Bornhauser M., Hanel M. et al. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplant 2005;36(12):1083–8.

106. Hahn T., Wall D., Camitta B. et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006;12(1):1–30.

107. Willemse M.J., Seriu T., Hettinger K. et al. Detection of minimal residual disease identified differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99(12):4386–93.

108. Kiehl M., Kraut L., Schwerdtfeger R. et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004;22(14):2816–25.

109. Felix C.A., Lange B., Chessells J.M. Pediatric acute lymphoblastic leukemia: challenges and controversies in 2000. Hematology Am Soc Hematol Educ Program 2000;:285–302.

110. Bunin N., Carston M., Wall D. et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002;99(9):3151–7.

111. Snyder D.S. Allogeneic stem cell transplantation for Philadelphia chromosome – positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2000;6(6):597–603.

112. Thomas D.A., Faderl S., Cortes J. et al. Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396–407.

113. Yanada M., Naoe T., Iida H. et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graftversus-host disease. Bone Marrow Transplant 2005;36(10):867–72.

114. Kroger N., Kruger W., WackerBackhaus G. et al. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome – positive acute lymphoblastic leukemia. Bone Marrow Transplant 1998;22(11):1029–33.

115. Deane M., Koh M., Foroni L. et al. FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Bone Marrow Transplant 1998;22(12):1137–43.

116. Mato A.R., Luger S. Autologous stem cell transplant in ALL: who should we be transplanting in first remission? Bone Marrow Transplant 2006;37(11):989–95.

117. Weisdorf D., Bishop M., Dharan B. et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcome. Biol Blood Marrow Transplant 2002;8(4):213–20.

118. Arico M., Valsecci M.G., Camitta B. et al. Outcome of treatment with Philadelphia chromosome – positive acute lymphoblastic leukemia. New Engl J Med 2000;34:998–1006.

119. Зубаровская Л.С., Сицкая К.О., Морозова Е.В., Афанасьев Б.В. Трансплантация стволовых гемопоэтических клеток при злокачественных заболеваниях системы крови у детей. Гематол трансфузиол 1998;(3):36–7.

120. Biondi A., Cazzaniga G. Molecular diagnosis and monitoring of acute lymphoblastic leukemia: applications and limitations. In: EHA, Educational book. 2000. p. 98–101.

121. Gorin N.C. Autologous stem cell transplantation in acute lymphoblastic leukemia. Stem cells 2002;20(1):3–10.

122. Fiere D., Lepage E., Sebban C. et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993;11(10):1990–2001.

123. Gorin N., Aegerter P., Auvert B. Autologous bone marrow transplantation for acute leukemia in remission: an analysis of 1322 cases. Haematol Blood Transfus 1990;33:660–6.

124. Tiley C., Powles R., Treleavan J. et al. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow Transplant 1993;12(5):449–55.

125. Blaise D., Attal M., Pico J.L. et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997;25(5–6):469–78.

126. Simonsson B., Burnett A.K., Prentice H.G. et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989;3(9):631– 6.

127. Doney K., Buckner C.D, Fisher L. et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1993;12(4):315–21.

128. Carey P., Proctor S., Taylor P. et al. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991;77(7):1593–8.

129. Lambertenghi Deliliers G., Mozzana R., Annaloro C. et al. Longterm results of autologous bone marrow transplantation in adult acute lymphoblastic leukemia. Leuk Lymphoma 1993;11(5–6):419–25.

130. Gilmore M.J., Hamon M.D., Prentice H.G. et al. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1991;8(1):19–26.

131. Vey N., Blaise D., Stoppa A.M. et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1994;14(3):383–8.

132. Powles R., Sirohi B., Treleaven J. et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002;100(5):1641–7.

133. Socie G., Salooja N., Cohen A. et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101(9):3373–85.

134. Wolff S.N. Second hematopoietic stem cell transplantation for the treatment of graft filure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002;29(7):545–52.

135. Zecca M., Prete A., Rondelli R. et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact of outcome. Blood 2002;100(4):1192–200.

136. Worel N., Greinix H.T., Keil F. et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002;42(10):1293–301.

137. Worel N., Kalhs P., Keil F. et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 2003;43(8):1153–61.

138. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(5):321–34.

139. Ringden O., Uzunel M., Rasmusson I. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81(10):1390–7.

140. Fukuchi Y., Nakajima H., Sugiyama D. et al. Human placenta-derived cells have mesenchymal stem/progenitor cell potencial. Stem cells 2004;22(5):649–58.

141. Lu L.L., Lui Y.J., Yang S.G. et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006;91(87):1017–26.